Date: 2013-07-26
Type of information: Private placement
Company: Polytherics (UK)
Investors: Imperial Innovations (UK) Invesco Perpetual (UK) Mercia Fund Management (UK) Advantage Enterprise & Innovation Fund (UK)
Amount: £13.5 million (€15,6 million)
Funding type: private placement
Planned used: The new funds will be used to fund the merger with Antitope and to provide working capital for the enlarged group.
Others: * On July 26, 2013, PolyTherics has announced that it is issuing new shares up to an aggregate value of £13.5 million (€15,6 million) to fund the merger with Antitope and to provide working capital for the enlarged group. Imperial Innovations led the investment and brought in new investor Invesco Perpetual with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.
Therapeutic area:
